Navigation Links
Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR

future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Myriad's development of Azixa will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with our ability to maintain our listing on The Nasdaq Capital Market; risks associated with our ability to have our common stock readmitted to trading on The Na
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. New Report Illuminates Ampligens Unique Mechanism of Action
6. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
7. Myriad Genetics Presents Azixas Mode of Action at AACR
8. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
9. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
10. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
11. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Mode Action EpiCept Licensed Cancer Compound Profiled AACR
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... Mo., Feb. 14, 2011 K-V Pharmaceutical Company (NYSE: ... into a definitive agreement with a group of institutional ... from a private placement of 9,950,000 shares of its ... Company will use $20 million of the proceeds from ...
... commonly prescribed osteoporosis drug is associated with a slightly ... osteonecrosis of the jaw; nonetheless the risk remains extremely ... Journal of Dental Research, the official journal of ... the findings are provocative, study authors say they should ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 2K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 3K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 4K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 5K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 6K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 7K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 8K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 9K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 10K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 11K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 12K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 13Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease 2Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease 3Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease 4
(Date:7/10/2014)... 10, 2014 Fatigue, lack of ... increasing number of accidents in the workplace, according ... The articles highlight safety issues that contribute to ... accidents occur on the job annually, according to ... to explore "preventable workplace accidents." , Safety Issue: ...
(Date:7/10/2014)... 10, 2014 Ticketability.com has a wide array ... Paul McCartney tickets for San Diego are being added to ... since 1976, and the newly added September 28 show is ... Click Here to view the selection of discounted ... Park will become available to the general public on July ...
(Date:7/10/2014)... Colorado (PRWEB) July 10, 2014 ... will gather in Copenhagen this July 13-17 to ... bringing the world closer to breakthroughs in dementia ... the world’s largest conference of its kind. , ... AAIC serves as a catalyst for generating new ...
(Date:7/10/2014)... July 10, 2014 One week ahead ... Worker Safety announced today it will extend compensation benefits ... months’ wages for workers displaced as a result of ... Alliance inspections have resulted in the closure of five ... five cases, raising immediate safety concerns. In May, the ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Register to ... DataSite recently streamed the live webinar ‘Capitalizing on the ... from a group of several M&A experts in the ... the broader energy transaction marketplace. These experts shared their ... the deal market in this sector has been revitalized. ...
Breaking Medicine News(10 mins):Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2
... Fourth Quarter ... -- Revises 2008 EPS Guidance Primarily to Reflect the Sale of Medical ... Imaging, -- Reaffirms Expected Non-GAAP EPS CAGR ... Through 2010, Subject to Certain Assumptions, -- Completes Sale of Medical Imaging Business, Reports ...
... The Procter &,Gamble Company (NYSE: PG ) announced ... the quarter. Sales were up behind strong volume growth,from ... in developing regions. Organic volume increased six percent and,organic ... earnings per,share increased 17 percent to $0.98 per share, ...
... can qualify for up to $100,000 in bonuses, ... nation,s largest effort to reward physicians for,delivery of high ... to providing health care by launching the BTE Medical ... have,adopted really good systems and processes of care, and ...
... ... in Canada ... 31 ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer and marketer of state-of-the-art ... and clarification from the US Food and Drug,Administration (FDA) regarding its PMA approval ...
... Easter Seals, with funding from the,Ludy Family Foundation ... program to help returning veterans with Traumatic Brain ... an in-home,computer-based cognitive training program -- and by ... Seals services and supports., Signature Wound, Significant ...
... MINNEAPOLIS, Jan. 31 A new survey ... of Minnesotans support the,statewide smoke-free law, with 44 ... of strong support among all leading,demographics, including geography, ... survey was conducted by Minneapolis research,firm Decision Resources, ...
Cached Medicine News:Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 2Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 3Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 4Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 5Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 6Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 7Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 8Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 9Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 10Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 11Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 12Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 13Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 14Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 15Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 16Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 17Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 18Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 19Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 20Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 21Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 22Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 23Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 24Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 25Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 26Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 27Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 28Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 29Health News:P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company 2Health News:P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company 3Health News:P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company 4Health News:P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company 5Health News:P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company 6Health News:P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company 7Health News:P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company 8
One inch disposable patch electrode uses a specially formulated adhesive solid gel. Reusable lead wire with snap connector provides economic benefits. Ideal for sleep studies where leg movement or EK...
... fabric, these head cap systems are packaged ... testing. Each Electro-Cap System features pure tin ... System. When you place your order, please ... your head cap system and whether you ...
... takes you into the OR, ER, or ICU, ... Cadwells new shielded electrodes. Keeping noise low and ... disc electrode has a special shielded cable that ... effects of 60-cycle interference. That means you get ...
... As opposed to the BIOM, the CWF and ... eye and require a contact medium such as ... to hold a contact lens steady, these lenses ... system. These lenses have an available detachable ...
Medicine Products: